Recent Finacing
Recent Raise
Ocuphire develops Nyxol, a preservative‑free phentolamine mesylate once‑daily ophthalmic drop for night-vision disturbances, glaucoma, mydriasis reversal and presbyopia, currently in Phase 2 trials with clinical partners.
